Stocks that may create buzz on Tuesday

Trident: Further expanding its retail presence across India, Trident Limited has opened six new exclusive showrooms across India for its bed & bath linen collections under Trident Home Décor Design thereby, taking the total count of its exclusive showrooms to 18. The newly-opened showrooms are located in Kolkata, Jaipur (two showrooms), Chandigarh, Mohali, and Karnal.  

Wipro: Wipro cited as a ‘leader’ in 2021 Gartner Magic Quadrant for managed workplace services, North America and Europe reports.   

ACC: Net sales grew by 22.7 per cent YoY to Rs 4,213 crore in Q1 2021. EBITDA jumped 46.8 per cent YoY to Rs 860 crore in Q1 2021. EBITDA margin stood at 20.4 per cent YoY and profit after tax jumped 74.2 per cent to Rs 563 crore in Q1 2021. Cement sales volume was up by 21.6 per cent YoY. Strong volume growth was driven by robust demand and low base impact. The company believes that the government is taking all possible steps to intensify the vaccination programme and control the spread of Coronavirus. With the government’s increased spending and its strong focus on infrastructure development, it maintains a cautious yet positive outlook for the overall cement demand in the coming months.   

Lyka Labs: The company has clarified that the message, which is being circulated on various social media platforms are false and misleading the public to believe that the company is having stock of Remdesivir injection.   

Adani Ports & Special Economic Zone: The board of directors of the company has approved the allotment of one crore equity shares of the face value of Rs 2 each fully paid-up, on a preferential basis to Windy Lakeside Investment Ltd at an issue price of Rs 800 per equity share (including a premium of Rs 798 per equity share), aggregating to Rs 8,00,00,00,000.   

Borosil Renewables: The board of directors of the company have considered and approved the expansion plan of the company to raise its production capacity of solar glass by an additional 1,000 tonnes per day (TPD) along with all processing capabilities in one or two phases. The estimated capital outlay will be Rs 1,000 crore.   

Kirloskar Brothers: Operations at Dewas plant of the company would be suspended temporarily from April 19 to April 26.   

Bajaj Consumer Care: In Q4FY21, the company has registered standalone sales growth of 43.5 per cent YoY while EBITDA witnessed a staggering jump of 148 per cent YoY and profit after tax soared about 120 per cent YoY to Rs 53.90 crore. To mitigate the impact of inflation, we have taken price increases of February 21 and March 21. The e-commerce business grew by 4x during Q4FY21. General trade witnessed a growth of 40 per cent YoY, alternate trade jumped 61.2 per cent YoY while total domestic trade grew by 42.7 per cent. International business registered a whopping growth of 83.8 per cent YoY.   

Supreme Petrochem: India Ratings & Research (Ind-Ra) has upgraded the company’s long-term rating to ‘IND AA-’ from ‘IND A+’ with stable outlook and confirmed short-term rating at ‘IND A1+’ for company’s fund and non-fund-based working capital facilities from banks.   

CRISIL: Income from operations for the quarter was up by 15.8 per cent YoY. Profit after tax for the quarter ended March 31, 2021, was Rs 83.5 crore, compared to Rs 88.1 crore in the corresponding quarter of the previous year. Foreign exchange loss for the quarter ended March 31, 2021, was Rs 4.7 crore compared with a gain of Rs 16.6 crore in the corresponding quarter of the previous year. Ashu Suyash, Managing Director & CEO of CRISIL says, “During the quarter, we saw good business momentum across ratings, research and analytics. Buoyant capital markets and new client acquisitions aided further growth. Ongoing demand for traded and credit-risk offerings also helped. We continue to make investments in data and technology capabilities, and in ensuring that our people are able to navigate well through the pandemic and serve clients.”  

Caplin Point Laboratories: Caplin Steriles gets USFDA approval for Milrinone lactate injection. C C Paarthipan, Chairman of Caplin Point Laboratories Limited commented, “We’re expecting approvals for 3 more products this quarter and we’re working on launches for 9 products in the next few months from the site.”